Lexapro (Escitalopram) Withdrawal: FDA-Documented Symptoms

SSRI discontinuation syndrome is not a single receptor phenomenon; it is the nervous system's response to the rapid withdrawal of chronically elevated synaptic serotonin. During SSRI treatment, sustained serotonin reuptake blockade produces compensatory downregulation of post-synaptic 5-HT receptors, particularly the 5-HT1A autoreceptor, alongside changes in serotonergic tone across cortical, limbic, and brainstem circuits. When the drug is removed and synaptic serotonin drops back toward baseline, the previously adapted receptor landscape is temporarily mismatched to the available neurotransmitter, and symptoms emerge until receptor systems re-adapt.

Serotonin is not the only implicated system. Cholinergic rebound is one accepted explanation for the flu-like symptoms and GI upset commonly reported during SSRI withdrawal; secondary effects on norepinephrine and dopamine circuits are invoked to account for symptoms such as agitation, low mood, and difficulty concentrating. The characteristic "brain zap" sensation — brief electrical shivers, often provoked by lateral eye movement — is thought to involve transient dysregulation in cortical and cerebellar serotonergic and GABAergic circuits, though the exact neurophysiology remains an active area of investigation. Because multiple systems are involved and re-adapt at different rates, symptoms tend to be heterogeneous rather than a single stereotyped syndrome. Some patients also describe symptoms that persist well beyond the acute window; a 2025 systematic review of post-acute withdrawal syndrome (PAWS) after stopping antidepressants found that a subset of patients report protracted symptoms, underscoring that discontinuation effects are neither universal nor uniformly brief (Rennwald A, et al. Post-acute withdrawal syndrome (PAWS) after stopping antidepressants: a systematic review. Epidemiol Psychiatr Sci. 2025;34:e29).

The clinical implication is straightforward: the faster the serotonergic input is withdrawn, the more pronounced the transient mismatch. A short-half-life SSRI removes serotonergic input steeply; a long-half-life SSRI removes it gradually. The taper strategy in the label — reduce the dose progressively rather than stopping abruptly — is a direct application of this pharmacology.

Within the SSRI class, half-life is one of the most useful predictors of acute discontinuation severity, and the class covers a wide range. Fluoxetine sits at one extreme, with a parent-drug half-life of 1–3 days and an active metabolite (norfluoxetine) of 7–15 days; that long tail acts as a built-in self-taper and is one reason fluoxetine discontinuation symptoms are frequently reported as milder and more delayed than with shorter-half-life agents. This same pharmacokinetic property is why clinicians sometimes bridge a difficult taper from a shorter-half-life antidepressant by substituting a course of fluoxetine before the final wean (Shapiro B, et al. Fluoxetine substitution for deprescribing antidepressants: a technical approach. J Psychiatry Neurosci. 2025;50(4):E202-E209). At the other extreme, paroxetine has a half-life of roughly 21 hours with no long-lived active metabolite, and — together with its added anticholinergic activity — is repeatedly identified in the literature as one of the SSRIs most likely to produce discontinuation symptoms.

Sertraline (half-life ~26 hours) and citalopram (half-life ~35 hours) sit in the middle of the range and are generally reported to produce moderate discontinuation profiles — meaningfully less severe than paroxetine but not as gentle as fluoxetine. Escitalopram, the S-enantiomer of citalopram, has a similar half-life to citalopram (~27–32 hours) and a similar overall discontinuation footprint in comparative reviews. These are population-level generalizations, not predictions for individual patients: some patients tolerate paroxetine tapers well, and others report significant symptoms discontinuing fluoxetine despite its long half-life.

Hyperbolic-tapering pharmacology — the principle that receptor occupancy falls off non-linearly as dose decreases, so equal milligram cuts produce progressively larger effects at low doses — was developed most extensively in the benzodiazepine and Z-drug literature but is now applied broadly across serotonergic and GABAergic medications when planning a physician-supervised wean (Horowitz M, et al. Pharmacological principles for safe benzodiazepine and Z-drug dose reduction. Psychol Med. 2026;56:e198). Applied to escitalopram, the practical takeaway is that the last small dose reductions are where discontinuation symptoms most commonly emerge, and that very slow, proportional reductions at the low end can meaningfully reduce risk. Because escitalopram's longer half-life produces a naturally gentler plasma decline, patients on it often tolerate straightforward physician-supervised tapers well, but a slow low-dose finish remains a reasonable option for anyone with a history of discontinuation-sensitive symptoms. No taper should be undertaken without the prescribing physician's guidance, and no one should stop escitalopram abruptly on their own.